Company news
Opus Genetics, Inc. news in 2025
Opus Genetics, Inc.'s news releases, calls and decks from 2025, newest first.
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 16, 2025
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference
December 11, 2025
Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease
December 9, 2025
Opus Genetics to Participate in Upcoming Investment Conferences
November 20, 2025
Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease
November 13, 2025
Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update
November 12, 2025
Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease
November 6, 2025
Opus Genetics Announces $23 Million Registered Direct Offering
November 6, 2025
Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness
November 3, 2025
Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference
October 14, 2025
Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025
October 2, 2025
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
September 30, 2025
Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions
September 4, 2025
Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
September 3, 2025
Opus Genetics Appoints Rob Gagnon as Chief Financial Officer
September 2, 2025
Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September
August 27, 2025
Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1
August 18, 2025
Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update
August 13, 2025
Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
August 5, 2025
Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness
July 23, 2025
Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 3, 2025
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
June 26, 2025
Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program
June 23, 2025
Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions
June 2, 2025
Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update
May 15, 2025
Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May
May 12, 2025
Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate
May 6, 2025
Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision
May 5, 2025
Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases
April 8, 2025
Opus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting the Company’s Transformation and Progress
April 7, 2025
Opus Genetics to Participate in Upcoming Investor Conference in April
April 2, 2025
Opus Genetics Announces Financial Results for Full Year 2024
March 31, 2025
Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX
March 21, 2025
Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million
March 21, 2025
Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
March 5, 2025
Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs
February 26, 2025
Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program
February 18, 2025
Decks in 2025
- Technical Presentation (September 2025)
Technical · 30 slides · Sep 30, 2025